The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to formula (I):
and salts thereof.
The compounds of the invention are inhibitors of kinase activity, in particular IKK2 activity.
PYRROLO[2,3-B]PYRIDIN-4-YL-BENZENESULFONAMIDE COMPOUNDS AS 1KK2 INHIBITORS
申请人:Bamborough Paul
公开号:US20100035917A1
公开(公告)日:2010-02-11
The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds according to Formula (1) and salts thereof. The compounds of the invention are inhibitors of kinase activity, in particular 1KK2 activity.
BENZPYRAZOL DERIVATIVES AS INHIBITORS OF PI3 KINASES
申请人:Baldwin Ian Robert
公开号:US20110178063A1
公开(公告)日:2011-07-21
The invention is directed to certain novel compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
该发明涉及公式(I)的某些新化合物及其盐。该发明的化合物是PI3-激酶活性的抑制剂。
Benzpyrazol derivatives as inhibitors of PI3 kinases
申请人:Baldwin Ian Robert
公开号:US08658635B2
公开(公告)日:2014-02-25
The invention is directed to certain novel compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of PI3-kinase activity.
该发明涉及公式(I)的某些新型化合物及其盐。该发明的化合物是PI3-激酶活性的抑制剂。
[EN] INHIBITORS OF URAT1 AND PHARMACEUTICAL USES THEREOF<br/>[FR] INHIBITEURS D'URAT1 ET UTILISATIONS PHARMACEUTIQUES ASSOCIÉES
申请人:NEXYS THERAPEUTICS INC
公开号:WO2022169974A1
公开(公告)日:2022-08-11
The present invention relates to pharmaceutical compounds, compositions, combinations, and methods, especially as they are related to compositions and methods for the treatment and/or prevention of conditions such as gout that are associated with excessive levels of uric acid. The invention provides compounds of Formula (I) as further described herein, which inhibit activity of urate reabsorption transporter 1 (URAT1, also known as SLC22A12). The compounds are useful to treat conditions associated with excessive levels of uric acid, such as gout.